CRISPR Therapeutics AG Stock News

CRISPR has incurred nearly $500 million in losses over the past four quarters. It's burning through cash as the result of its its gene-editing therapy's slow rollout.

A $1,000 investment can be an ideal amount to invest in an up-and-coming growth stock. The stocks below are still modest in size, with market capitalization of less than $6 billion.

CRISPR Therapeutics and Viking Therapeutics are innovative biotechs with attractive pipelines. Both could see their shares soar as they make consistent clinical and regulatory progress.

There are only 12 investing days left in 2025. Now is a great time to load up on stocks that may win next year -- and over time.

CRISPR Therapeutics could soar on the back of significant pipeline progress next year. Vertex's slow and steady approach to diversifying its lineup should eventually pay off.

CRISPR Therapeutics' approved medicine is making slow progress, but it has an exciting pipeline. Iovance Biotherapeutics is generating decent revenue, but it faces significant obstacles.

Crispr Therapeutics AG remains a Strong Buy, driven by forthcoming revenue following Casgevy's FDA/EMA approvals and a robust, expanding pipeline targeting high-value indications. CRSP's commercial launch of Casgevy is progressing, with their share of a $100M+ 2025 total revenue expectation, and significant growth expected into 2026. The pipeline's cardiovascular assets (CTX310/320) show promis...

Cathie Wood aims to identify innovators and invest in them early in their stories. Wood has been regularly adding to her position in this stock, and it's one of her top holdings.